NovaBay Pharmaceuticals Net Income
| NBY Stock | USD 0.52 0.06 10.34% |
As of the 17th of February 2026, NovaBay Pharmaceuticals secures the Risk Adjusted Performance of 0.0489, mean deviation of 13.66, and Downside Deviation of 17.06. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NovaBay Pharmaceuticals, as well as the relationship between them.
NovaBay Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 6.8305 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -6.5 M | -6.8 M | |
| Net Loss | -7.7 M | -8.1 M | |
| Net Loss | -8.3 M | -8.7 M | |
| Net Loss | (1.91) | (2.01) | |
| Net Income Per E B T | 0.90 | 0.83 |
NovaBay | Net Income | Build AI portfolio with NovaBay Stock |
The evolution of Net Income for NovaBay Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how NovaBay Pharmaceuticals compares to historical norms and industry peers.
Latest NovaBay Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of NovaBay Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in NovaBay Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of NovaBay Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is NovaBay Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NovaBay Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (7.21 M) | 10 Years Trend |
|
Net Income |
| Timeline |
NovaBay Net Income Regression Statistics
| Arithmetic Mean | (9,277,379) | |
| Coefficient Of Variation | (48.75) | |
| Mean Deviation | 3,539,526 | |
| Median | (7,403,000) | |
| Standard Deviation | 4,522,923 | |
| Sample Variance | 20.5T | |
| Range | 18M | |
| R-Value | 0.09 | |
| Mean Square Error | 21.6T | |
| R-Squared | 0.01 | |
| Significance | 0.72 | |
| Slope | 83,074 | |
| Total Sum of Squares | 327.3T |
NovaBay Net Income History
Other Fundumenentals of NovaBay Pharmaceuticals
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
NovaBay Pharmaceuticals Net Income component correlations
NovaBay Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for NovaBay Pharmaceuticals is extremely important. It helps to project a fair market value of NovaBay Stock properly, considering its historical fundamentals such as Net Income. Since NovaBay Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NovaBay Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NovaBay Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NovaBay Pharmaceuticals. Anticipated expansion of NovaBay directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive NovaBay Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 5.16 | Revenue Per Share | Quarterly Revenue Growth (0.79) | Return On Assets | Return On Equity |
NovaBay Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on NovaBay's balance sheet. Smart investors calculate NovaBay Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since NovaBay Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between NovaBay Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NovaBay Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, NovaBay Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
NovaBay Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to NovaBay Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of NovaBay Pharmaceuticals.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in NovaBay Pharmaceuticals on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding NovaBay Pharmaceuticals or generate 0.0% return on investment in NovaBay Pharmaceuticals over 90 days. NovaBay Pharmaceuticals is related to or competes with Quoin Pharmaceuticals, Impact BioMedical, Pasithea Therapeutics, Addex Therapeutics, Matinas BioPharma, PharmaCyte Biotech, and Alaunos Therapeutics. NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United ... More
NovaBay Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure NovaBay Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess NovaBay Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 17.06 | |||
| Information Ratio | 0.0455 | |||
| Maximum Drawdown | 158.53 | |||
| Value At Risk | (29.80) | |||
| Potential Upside | 33.7 |
NovaBay Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for NovaBay Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as NovaBay Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use NovaBay Pharmaceuticals historical prices to predict the future NovaBay Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0489 | |||
| Jensen Alpha | 0.8008 | |||
| Total Risk Alpha | (0.59) | |||
| Sortino Ratio | 0.0601 | |||
| Treynor Ratio | 0.229 |
NovaBay Pharmaceuticals February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0489 | |||
| Market Risk Adjusted Performance | 0.239 | |||
| Mean Deviation | 13.66 | |||
| Semi Deviation | 15.86 | |||
| Downside Deviation | 17.06 | |||
| Coefficient Of Variation | 2055.49 | |||
| Standard Deviation | 22.5 | |||
| Variance | 506.3 | |||
| Information Ratio | 0.0455 | |||
| Jensen Alpha | 0.8008 | |||
| Total Risk Alpha | (0.59) | |||
| Sortino Ratio | 0.0601 | |||
| Treynor Ratio | 0.229 | |||
| Maximum Drawdown | 158.53 | |||
| Value At Risk | (29.80) | |||
| Potential Upside | 33.7 | |||
| Downside Variance | 290.96 | |||
| Semi Variance | 251.58 | |||
| Expected Short fall | (16.07) | |||
| Skewness | 1.87 | |||
| Kurtosis | 7.73 |
NovaBay Pharmaceuticals Backtested Returns
NovaBay Pharmaceuticals is out of control given 3 months investment horizon. NovaBay Pharmaceuticals has Sharpe Ratio of 0.0561, which conveys that the firm had a 0.0561 % return per unit of risk over the last 3 months. We have analyzed twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.32% are justified by taking the suggested risk. Use NovaBay Pharmaceuticals Mean Deviation of 13.66, risk adjusted performance of 0.0489, and Downside Deviation of 17.06 to evaluate company specific risk that cannot be diversified away. NovaBay Pharmaceuticals holds a performance score of 4 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 4.74, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, NovaBay Pharmaceuticals will likely underperform. Use NovaBay Pharmaceuticals sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to analyze future returns on NovaBay Pharmaceuticals.
Auto-correlation | -0.79 |
Almost perfect reverse predictability
NovaBay Pharmaceuticals has almost perfect reverse predictability. Overlapping area represents the amount of predictability between NovaBay Pharmaceuticals time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of NovaBay Pharmaceuticals price movement. The serial correlation of -0.79 indicates that around 79.0% of current NovaBay Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.79 | |
| Spearman Rank Test | -0.93 | |
| Residual Average | 0.0 | |
| Price Variance | 28.05 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
NovaBay Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, NovaBay Pharmaceuticals reported net income of (7.21 Million). This is 102.11% lower than that of the Pharmaceuticals sector and 110.29% lower than that of the Health Care industry. The net income for all United States stocks is 101.26% higher than that of the company.
NovaBay Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NovaBay Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NovaBay Pharmaceuticals could also be used in its relative valuation, which is a method of valuing NovaBay Pharmaceuticals by comparing valuation metrics of similar companies.NovaBay Pharmaceuticals is currently under evaluation in net income category among its peers.
NovaBay Fundamentals
| Return On Equity | -5.16 | ||||
| Return On Asset | -0.87 | ||||
| Profit Margin | 0.31 % | ||||
| Operating Margin | (2.24) % | ||||
| Current Valuation | 70.37 M | ||||
| Shares Outstanding | 129.61 M | ||||
| Shares Owned By Insiders | 91.87 % | ||||
| Shares Owned By Institutions | 5.14 % | ||||
| Number Of Shares Shorted | 2.7 M | ||||
| Price To Earning | (5.43) X | ||||
| Price To Book | 2.17 X | ||||
| Price To Sales | 6.59 X | ||||
| Revenue | 9.78 M | ||||
| Gross Profit | 6.52 M | ||||
| EBITDA | (5.92 M) | ||||
| Net Income | (7.21 M) | ||||
| Cash And Equivalents | 430 K | ||||
| Cash Per Share | 0.07 X | ||||
| Total Debt | 1.67 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 2.59 X | ||||
| Book Value Per Share | (0.45) X | ||||
| Cash Flow From Operations | (5.18 M) | ||||
| Short Ratio | 1.19 X | ||||
| Earnings Per Share | 5.16 X | ||||
| Target Price | 0.85 | ||||
| Number Of Employees | 13 | ||||
| Beta | 0.007 | ||||
| Market Capitalization | 67.91 M | ||||
| Total Asset | 3.42 M | ||||
| Retained Earnings | (183.46 M) | ||||
| Working Capital | (908 K) | ||||
| Current Asset | 4.53 M | ||||
| Current Liabilities | 4.63 M | ||||
| Annual Yield | 0.34 % | ||||
| Net Asset | 3.42 M |
About NovaBay Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NovaBay Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NovaBay Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NovaBay Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.